Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | CD44 | P16070 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11737280 | 0.76 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL6202610 | 0.73 | HTR2C (0.57) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL29407560 | 0.73 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL11746068 | 0.73 | HTR2A (0.77) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL11734649 | 0.73 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL22993473 | 0.73 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL30098019 | 0.73 | PNMT (0.54) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| Hydrochloric Acid SCHEMBL23727152 | 0.72 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| Hydrochloric Acid SCHEMBL23725622 | 0.72 | HTR2A (0.74) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL23036826 | 0.72 | PNMT (0.57) | PNMTADRA2AADRA2BADRA2CCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232360-B2 | Stereoregular ROMP polymers | RESEARCH FOUNDATION OF STATE UNIVERSITY OF N.Y. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110251363-A1 | STEREOREGULAR ROMP POLYMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | disclosed |
| WO-2008019217-A2 | STEREOREGULAR ROMP POLYMERS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2005059098-A2 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING NEURODEGENERATIVE CONDITIONS | CREIGHTON UNIVERSITY (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251363-A1 | STEREOREGULAR ROMP POLYMERS | PCBP1, PARG, OSGEP | PNMT 2403/4885ADRA2A 3683/4885ADRA2B 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.